Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

Recruiting Observational Study
Long Term Follow-up
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
20 – 70
Sex
Any
Study type
Observational
Participants needed
50 (estimated)
Sponsor
Arbutus Biopharma Corporation · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[EOS\] visit) from their imdusiran clinical trial (the "parent study"). No…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: * Have participated in a prior imdusiran clinical trial, * Have discontinued NA therapy in that trial and remain off NA therapy, * Have completed less than 3 years of follow-up visits after NA discontinuation in the parent study. * Have the ability to review and provide sign…
Contacts

Michael Child

267-332-6213

mchild@arbutusbio.com

CONTACT